This reduces the activity of RAC-GAPs, to maintain RAC1 in its GTP bound state (39), working in concert with RAC1 signalling pathway members to significantly increase the amount of RAC1-GTP in AML after CKS1i treatment (Figure 5C, Supp. This evidence concerns the gene RAC1 and acute myeloid leukemia.